Of therapeutic relevance, fenofibrate, a potent PPARα agonist originally considered to have roles in lipid regulation [102], anti-inflammation [103,104], and anti-apoptosis [105], has shown promise in clinical trials as a possible oral treatment option for diabetic retinopathy by preventing microvascular complications [106]. Here, PPARA is linked to diabetic retinopathy.